Moncef Slaoui
| Moncef Slaoui | |
|---|---|
 Slaoui dengan CEO GlaxoSmithKline Emma Walmsley (Desember 2016) | |
| Lahir | Moncef Mohamed Slaoui 22 Juli 1959 Agadir, Maroko |
| Kebangsaan | Maroko |
| Kewarganegaraan | |
| Pendidikan | Université libre de Bruxelles (BS, MS, PhD) International Institute for Management Development (MBA) |
| Dikenal atas | Operasi Warp Speed |
| Anak | 3 |
| Karier ilmiah | |
| Bidang | |
| Institusi | |
| Disertasi | Etude de la diversité et de la sélection des répertoires idiotypiques dans le système immunitaire (1983) |
| Pembimbing doktoral | Jacques Urbain |
Moncef Mohamed Slaoui[1] (lahir 22 Juli 1959) adalah seorang peneliti Belgia-Amerika kelahiran Maroko dan mantan kepala departemen vaksin GlaxoSmithKline.[2] Ia bekerja di perusahaan tersebut selama tiga puluh tahun, pensiun pada 2017. Pada 15 Mei 2020, Presiden Donald Trump mengumumkan bahwa Slaoui bakal mengurusi pengembangan vaksin pemerintah Amerika Serikat yang dipakai untuk mengobati penyakit koronavirus dalam Operasi Warp Speed.[3]
Karya pilihan dan publikasi
Karya
Scholia memiliki profil author tentang Moncef Slaoui.
- Slaoui, Mohamed Monsif (1983). Etude de la diversité et de la sélection des répertoires idiotypiques dans le système immunitaire (dalam bahasa Prancis). Bruxelles: Université libre de Bruxelles, Faculté des sciences.
identifier: ulbcat.ulb.ac.be:537608
- Rosenthal, Susan L.; Stanberry, Lawrence R.; Biro, Frank M.; Slaoui, Moncef; Francotte, Myriam; Koutsoukos, Marguerite; Hayes, Marianne; Bernstein, David I. (February 1997). "Seroprevalence of Herpes Simplex Virus Types 1 and 2 and Cytomegalovirus in Adolescents". Clinical Infectious Diseases. 24 (2): 135–139. doi:10.1093/clinids/24.2.135. Templat:Wikidata+icon
- Keadle, Tammie L.; Laycock, Keith A.; Miller, Judith Kelvin; Hook, Kelly K.; Fenoglio, E. D.; Francotte, Myriam; Slaoui, Moncef; Stuart, P. Michael; Pepose, Jay S. (August 1997). "Efficacy of a Recombinant Glycoprotein D Subunit Vaccine on the Development of Primary and Recurrent Ocular Infection with Herpes Simplex Virus Type 1 in Mice". The Journal of Infectious Diseases. 176 (2): 331–338. doi:10.1086/514049. PMID 9237697. Templat:Wikidata+icon
- Stanberry, Lawrence R.; Spruance, Spotswood L.; Cunningham, Anthony L.; Bernstein, David I.; Mindel, Adrian; Sacks, Stephen; Tyring, Stephen; Aoki, Fred Y.; Slaoui, Moncef; Denis, Martine; Vandepapeliere, Pierre; Dubin, Gary (November 21, 2002). "Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes". The New England Journal of Medicine. 347 (21): 1652–1661. doi:10.1056/NEJMOA011915. PMID 12444179. Templat:Wikidata+icon
- Bourne, Nigel; Bravo, Fernando J.; Francotte, Myriam; Bernstein, David I.; Myers, Martin G.; Slaoui, Moncef; Stanberry, Lawrence R. (February 15, 2003). "Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV‐1 or HSV‐2 Disease in Guinea Pigs". The Journal of Infectious Diseases. 187 (4): 542–549. doi:10.1086/374002. PMID 12599070. Templat:Wikidata+icon
- Slaoui, Moncef (April 23, 2010). "The rise and fall of rosiglitazone: reply". European Heart Journal. 31 (10): 1282–1284. doi:10.1093/EURHEARTJ/EHQ118. PMID 20499440. Templat:Wikidata+icon
- Famm, Kristoffer; Litt, Brian; Tracey, Kevin J.; Boyden, Edward S.; Slaoui, Moncef (April 10, 2013). "A jump-start for electroceuticals". Nature. 496 (7444): 159–161. doi:10.1038/496159A. PMC 4179459. PMID 23579662. Templat:Wikidata+icon
- Uguen, David; Lönngren, Thomas; Le Cam, Yann; Garner, Sarah; Voisin, Emmanuelle; Incerti, Carlo; Dunoyer, Marc; Slaoui, Moncef (2014). "Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives". Orphanet Journal of Rare Diseases. 9 (1): 20. doi:10.1186/1750-1172-9-20. PMC 3923002. PMID 24513034. Templat:Wikidata+icon
Publikasi
- Slaoui, Moncef (July 1, 2013). "It's Time to Further Incentivize Medical Innovation". Huffington Post.
Referensi
- ^ US Expired 8597656B2, Cabezon, Teresa Silva; Slaoui, Moncef Mohamed & Cohen, Joseph et al., "Process for the production of immunogenic compositions", diterbitkan tanggal March 12, 2013, dikeluarkan tanggal March 12, 2013, diberikan kepada GlaxoSmithKline Biologicals SA
- ^ Mullard, Asher (July 1, 2015). "Moncef Slaoui". Nature Reviews Drug Discovery. 14 (7): 452–453. doi:10.1038/NRD4669. PMID 26129795. Templat:Wikidata+icon
- ^ Sanger, David E.; Haberman, Maggie; Weiland, Noah (May 15, 2020). "Trump Vows Vaccine by End of Year, and Mobilizes Military to Help". The New York Times.
Bacaan tambahan
- Mullard, Asher (July 1, 2015). "Moncef Slaoui". Nature Reviews Drug Discovery. 14 (7): 452–453. doi:10.1038/NRD4669. PMID 26129795. Templat:Wikidata+icon
Pranala luar
Wikimedia Commons memiliki media mengenai Moncef Slaoui.
- Daftar publikasi dari Microsoft Academic Search
- Publikasi oleh Moncef Slaoui, di ResearchGate
- Moncef Slaoui dari basis data pustaka Scopus
- {{Twitter}} templat tidak dilengkapi ID dan tidak muncul di Wikidata.
| Basis data pengawasan otoritas: Akademik |
|---|
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.